Mucosat solution 100mg/ml 2ml ampoules, 5pcs

Composition

Active ingredient:

chondroitin sodium sulfate 100 mg;

Auxiliary substances:

benzyl alcohol-9 mg,

d/i water-up to 1 ml

Pharmacological action

Pharmacotherapy group

Tissue repair stimulator.

ATX code M01AX25

Pharmacological action

The drug has a chondroprotective, stimulating regeneration of cartilage tissue, anti-inflammatory effect. It participates in the construction of the main substance of cartilage and bone tissue, improves phosphorus-calcium metabolism in cartilage tissue, inhibits enzymes that disrupt the structure and function of articular cartilage, and inhibits the processes of cartilage degeneration. It stimulates the synthesis of proteoglycans, normalizes the metabolism of hyaline cartilage, and promotes the regeneration of cartilage surfaces and joint bags. It prevents compression of connective tissue, increases the production of synovial fluid and mobility of affected joints, reduces concomitant inflammation, soreness, and helps reduce the need for NSAIDs. In case of degenerative changes in the cartilage tissue, it is a means of replacement therapy.

A positive effect is observed as early as 2-3 weeks after the start of drug use. The therapeutic effect persists for a long time (3-6 months) after the end of the course of treatment.

Pharmacokinetics:

Chondroitin sodium sulfate is easily absorbed after intramuscular use. After 30 minutes, it is detected in the blood in significant concentrations: the maximum concentration is reached in 1 hour, then its content gradually decreases over 2 days.

Chondroitin sulfate sodium accumulates mainly in the cartilage tissue.

The synovial membrane is not an obstacle to its penetration into the joint cavity. 15 minutes after an intramuscular injection of chondroitin, sodium sulfate is detected in the synovial fluid, then it enters the articular cartilage, where its content reaches a maximum after 48 hours.

Indications

Degenerative-dystrophic diseases of the joints and spine:

– osteoarthritis of the peripheral joints;

– intervertebral osteochondrosis and osteoarthritis.

To accelerate the formation of bone callus in fractures.

Use during pregnancy and lactation

Currently, there are no data on the use of the drug Mukosat® during pregnancy and lactation, as well as in children.

Contraindications

Hypersensitivity, tendency to bleeding, thrombophlebitis.

Side effects

Possible allergic reactions and hemorrhages at the injection site. In these cases, the drug is canceled.

Interaction

When undergoing a course of treatment with the drug “Mukosat®”, care should be taken with the simultaneous use of direct-acting anticoagulants. It is also possible to increase the effect of non-direct anticoagulants, antiplatelet agents and fibrinolytics.

How to take, course of use and dosage

Medication Mucosate is administered intravenously in 1 ml every other day.

If well tolerated, the dose is increased to 2 ml, starting with the fourth injection.

The course of treatment is 25-30 injections.

If necessary, it is possible to conduct repeated courses in 6 months.

Form of production

Solution for intramuscular use

Storage conditions

In a dark place, at a temperature of 0-20 °C.

Shelf life

3 years

Active ingredient

Chondroitin sulfate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For adults as directed by your doctor

Indications

Arthritis, Osteoarthritis, Osteoarthritis, Osteochondrosis